Russell Investments Group, Ltd. Myovant Sciences Ltd. Transaction History

Russell Investments Group, Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$11.38 - $16.4 $99,688 - $143,664	-8,760 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$14.31 - $23.87 $29,392 - $49,028	-2,054 Reduced 18.99%	8,760 $140,000
Q3 2021 Nov 08, 2021	BUY	$18.94 - $26.99 $102,711 - $146,366	5,423 Added 100.59%	10,814 $241,000
Q2 2021 Aug 04, 2021	SELL	$17.07 - $24.56 $20,637 - $29,693	-1,209 Reduced 18.32%	5,391 $121,000
Q1 2021 May 10, 2021	SELL	$20.46 - $25.18 $1.54 Million - $1.89 Million	-75,084 Reduced 91.92%	6,600 $135,000
Q4 2020 Feb 08, 2021	SELL	$13.8 - $27.62 $436,080 - $872,792	-31,600 Reduced 27.89%	81,684 $2.25 Million
Q3 2020 Nov 09, 2020	BUY	$14.05 - $22.6 $1.59 Million - $2.56 Million	113,284 New	113,284 $1.6 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.